TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31181022

Group type: EXPERIMENTAL
Intervention: Buzzy device (cold and vibration)
Number of subjects: 607

Group type: COMPARATOR
Intervention: EMLA patch (standard care)
Number of subjects: 607
Study: 31765604

Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Number of subjects: 690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690
Study: 28950725

Group type: EXPERIMENTAL
Intervention: Exercise intervention (12-week program, 30 min/day)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Comparison health and wellness intervention
Number of subjects: 241
Study: 26001905

Group type: EXPERIMENTAL
Intervention: 60% sorghum diet and 40% rice diet (Experimental Group)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Regular rice diet (100%; Control Group)
Number of subjects: 320
Study: 24927118

Group type: EXPERIMENTAL
Intervention: SevoBIS (n=31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevo1.8% (n=29)
Number of subjects: 60
Study: 22301204

Group type: EXPERIMENTAL
Intervention: Ramp position
Number of subjects: 189

Group type: COMPARATOR
Intervention: Sniff position
Number of subjects: 189
Study: 20393347

Group type: EXPERIMENTAL
Intervention: Extended buprenorphine/naloxone therapy (BUP) for 12 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Detoxification for 2 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both interventions (BUP and detoxification)
Number of subjects: 150
Study: 18350637

Group type: EXPERIMENTAL
Intervention: Esomeprazole enteric-coated capsules (40 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Esomeprazole magnesium (40 mg)
Number of subjects: 60
Study: 16228116

Group type: EXPERIMENTAL
Intervention: Wearing Fatal Vision goggles
Number of subjects: 251

Group type: COMPARATOR
Intervention: Watching those wearing the goggles
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group 1
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group 2
Number of subjects: 251
Study: 12075272

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (6 1-g capsules providing 3 g eicosapentaenoic acid and 2.1 g docosahexaenoic acid/d)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 339
Study: 10479129

Group type: EXPERIMENTAL
Intervention: Zidovudine/didanosine (ddI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Zidovudine/ddI/nevirapine
Number of subjects: 55
Study: 8141537

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (DuoDerm Extra Thin CGF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Gauze dressing (Xeroform)
Number of subjects: 28
Study: 3375323

Group type: EXPERIMENTAL
Intervention: Quantitative Group (n = 19) using trend-line approach
Number of subjects: 39

Group type: COMPARATOR
Intervention: Visual Group (n = 20) using visual-inspection approach
Number of subjects: 39
Study: 29603547

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both groups (CGM and standard treatment)
Number of subjects: 300
Study: 28760648

Group type: EXPERIMENTAL
Intervention: High-impact chronic pain
Number of subjects: 1925

Group type: EXPERIMENTAL
Intervention: Lowest wealth quartile
Number of subjects: 1925

Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 1925

Group type: EXPERIMENTAL
Intervention: Arthritis and depression
Number of subjects: 1925
Study: 24219890

Group type: EXPERIMENTAL
Intervention: Rice chewed 15 times
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rice chewed 30 times
Number of subjects: 15
Study: 22395583

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1600 IU cholecalciferol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19996335

Group type: EXPERIMENTAL
Intervention: 6 minute walk test (6MWT)
Number of subjects: 123
Study: 18446021

Group type: EXPERIMENTAL
Intervention: 500 mg of ascorbic acid and 400 IU of alpha-tocopherol for 6 months
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 1,000 mg of ascorbic acid and 400 IU of alpha-tocopherol for 6 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 15872344

Group type: EXPERIMENTAL
Intervention: SPECT with attenuation correction
Number of subjects: 23

Group type: COMPARATOR
Intervention: SPECT without attenuation correction
Number of subjects: 23

Group type: COMPARATOR
Intervention: PET with (13)N-ammonia
Number of subjects: 23
Study: 12881451

Group type: EXPERIMENTAL
Intervention: Xuezhikang (1200 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10560218

Group type: EXPERIMENTAL
Intervention: Home-based multisystemic therapy (MST)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Inpatient hospitalization
Number of subjects: 116
Study: 8827790

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) levels in anemic newborns
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hb levels in IUTd and non-IUTd cases
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epo levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reticulocyte count
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation between Epo and Hb
Number of subjects: 30
Study: 1593034

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study: 6398983

Group type: EXPERIMENTAL
Intervention: Individual intervention group
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201

Group type: COMPARATOR
Intervention: Monitored group
Number of subjects: 201
Study: 30550982

Group type: EXPERIMENTAL
Intervention: Pre-stimulation with anti-CD3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplements (16 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-cellular flowcytometry analysis
Number of subjects: 0
Study: 30104047

Group type: EXPERIMENTAL
Intervention: PPF-treated LLINs (permethrin plus pyriproxyfen)
Number of subjects: 4137

Group type: COMPARATOR
Intervention: Standard LLINs (permethrin-only)
Number of subjects: 4137
Study: 26312616

Group type: EXPERIMENTAL
Intervention: 30 min of the Stroop task (mentally fatiguing treatment)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 30 min of reading magazines (control treatment)
Number of subjects: 26
Study: 25382974

Group type: EXPERIMENTAL
Intervention: Life Story Work Program (LSWp)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual activities (Control)
Number of subjects: 60
Study: 22261578

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation (1.7 g of cis-9,trans-11 and trans-10,cis-12 CLA in 200 mL of sterilized milk twice daily for 12 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (salad oil in 200 mL of sterilized milk twice daily for 12 weeks)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation
Number of subjects: 63
Study: 19703922

Group type: EXPERIMENTAL
Intervention: Inner-quadrant tumors (n = 393)
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Outer-quadrant tumors (n = 852)
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Left-sided breast cancer
Number of subjects: 1245
Study: 17484381

Group type: EXPERIMENTAL
Intervention: Test food (40 mg of soy isoflavone aglycone per day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo food
Number of subjects: 26
Study: 16326296

Group type: EXPERIMENTAL
Intervention: Stellate ganglion blockade (SGB) performed on 19 patients before anesthesia induction
Number of subjects: 37

Group type: COMPARATOR
Intervention: Norepinephrine (NE) applied to determine contractile force
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Stellate ganglion blockade (SGB)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control and blocked IMA segments
Number of subjects: 37
Study: 11932472

Group type: EXPERIMENTAL
Intervention: Sulindac (75 or 150 mg orally twice a day for 48 months)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (identical-appearing tablets for 48 months)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 41
Study: 9751323

Group type: EXPERIMENTAL
Intervention: Mitoxantrone in combination with steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estramustine combinations with vinblastine, etoposide or paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary hormonal therapies (alternative antiandrogens and anti‐adrenal agents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of prostate specific antigen values with quality of life and measurable disease responses
Number of subjects: 0
Study: 7790732

Group type: EXPERIMENTAL
Intervention: Indomethacin pretreatment (50 mg suppository administered 30 min before hyperthermia)
Number of subjects: 5

Group type: COMPARATOR
Intervention: No indomethacin pretreatment (control)
Number of subjects: 5
Study: 1722918

Group type: EXPERIMENTAL
Intervention: Org 10172 (Lomoparan, i.v. bolus injection of 3,250 anti‐Xa units followed by 750 units twice daily s.c. for 8 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (500 mg orally 14 and 2 h before i.v. Org 10172 administration)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Org 10172 and ASA combined
Number of subjects: 8

Group type: COMPARATOR
Intervention: Org 10172 alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: ASA alone
Number of subjects: 8
Study: 7152443

Group type: EXPERIMENTAL
Intervention: Combined low-dose uricostatic and uricosuric regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30805830

Group type: EXPERIMENTAL
Intervention: Group-delivered HIV risk reduction intervention (4 group sessions, 2 hours each)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Group-delivered HIV risk reduction intervention
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (n=6)
Number of subjects: 14
Study: 28700816

Group type: COMPARATOR
Intervention: Placebo/Nocebo
Number of subjects: 446
Study: 25915826

Group type: EXPERIMENTAL
Intervention: Daily consumption of one portion of cake fortified with barley's beta‐glucan
Number of subjects: 23

Group type: COMPARATOR
Intervention: Daily consumption of the same cake without the enrichment (placebo)
Number of subjects: 23
Study: 24495660

Group type: EXPERIMENTAL
Intervention: Famous face
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Famous scene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scrambled image
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroimaging (fMRI) for remember responses to words studied with famous faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroimaging (fMRI) for remember responses to words studied with famous scenes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Know responses
Number of subjects: 0
Study: 21406493

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 20009964

Group type: EXPERIMENTAL
Intervention: aPV at birth and 1 month
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: aPV at birth only
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study: 17100971

Group type: EXPERIMENTAL
Intervention: Wireless pH monitoring
Number of subjects: 31

Group type: COMPARATOR
Intervention: Catheter-based pH monitoring
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Preference for wireless pH monitoring
Number of subjects: 31
Study: 15705733

Group type: EXPERIMENTAL
Intervention: World-class Spanish male endurance athletes
Number of subjects: 104

Group type: COMPARATOR
Intervention: Spanish men (n = 164)
Number of subjects: 104
Study: 11870807

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9854508

Group type: EXPERIMENTAL
Intervention: EET therapy (intravenous administration of IFN‐gamma or TNF‐SAM2 followed by OK‐432)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: EET therapy (more than 5 courses)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: EET therapy
Number of subjects: 75
Study: 7874902

Group type: EXPERIMENTAL
Intervention: Esophageal balloon protocol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Clinical protocol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 23
Study: 2212408

Group type: EXPERIMENTAL
Intervention: Inhaled adenosine 5'-monophosphate (AMP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no AMP)
Number of subjects: 8
Study: 329291

Group type: EXPERIMENTAL
Intervention: 250 micrograms/kg N,N‐dimethyltryptamine (DMT) i.m.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31472930

Group type: EXPERIMENTAL
Intervention: Planned delivery
Number of subjects: 901

Group type: COMPARATOR
Intervention: Expectant management (usual care)
Number of subjects: 901
Study: 28659252

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotional SMS messages 3 times a week
Number of subjects: 353

Group type: COMPARATOR
Intervention: Maternal and child health care messages (excluding breastfeeding-related messages) once a week
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Child morbidity and breastfeeding self-efficacy scores assessed at 1, 3, and 5 months postdelivery
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Social desirability measured at 5 months
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Text messages expressing delivery success and user experience assessed at the end of the study
Number of subjects: 353
Study: 26349123

Group type: EXPERIMENTAL
Intervention: Experimental dentifrice formulations (1450 ppm fluoride) with 2% isopentane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental dentifrice formulations (1450 ppm fluoride) without 2% isopentane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive control dentifrice (1450 ppm fluoride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control dentifrice (0 ppm fluoride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% isopentane dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0% isopentane dentifrice
Number of subjects: 0
Study: 23816493

Group type: EXPERIMENTAL
Intervention: Family-focused integrated package of PMTCT services including task-shifting and point-of-care CD4 + cell count testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (not explicitly mentioned but implied as control)
Number of subjects: 0
Study: 22309473

Group type: COMPARATOR
Intervention: Neutral description of the child
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Anxious description of the child
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Audio vignette intervention
Number of subjects: 124
Study: 19883313

Group type: EXPERIMENTAL
Intervention: Thalidomide therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Presence of T cell expansions (regardless of therapy)
Number of subjects: 120
Study: 17565163

Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training with FFOV task
Number of subjects: 0
Study: 15112860

Group type: EXPERIMENTAL
Intervention: Morphine sulfate (10 mg i.v.)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 11552902

Group type: EXPERIMENTAL
Intervention: Ridogrel (5 mg/day for 12 weeks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 9631813

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) delivering 100 microg of methacholine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional nebulizer delivering methacholine
Number of subjects: 40
Study: 7697689

Group type: EXPERIMENTAL
Intervention: Sustained-release cream
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard cream
Number of subjects: 16
Study: 3666661

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg orally)
Number of subjects: 6
Study: 31922999

Group type: EXPERIMENTAL
Intervention: Midazolam (0.04 mg·kg)
Number of subjects: 406
Study: 29433481

Group type: EXPERIMENTAL
Intervention: Exercise therapy alone
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Exercise therapy plus early ACLR
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Exercise therapy plus delayed ACLR
Number of subjects: 121

Group type: COMPARATOR
Intervention: Physical performance tests (hop, strength, balance)
Number of subjects: 121
Study: 27126856

Group type: EXPERIMENTAL
Intervention: Risperidone monotherapy
Number of subjects: 124
Study: 25515553

Group type: EXPERIMENTAL
Intervention: Botanical oil (BO) combination (borage/echium oil)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Corn oil (CO)
Number of subjects: 59
Study: 22901969

Group type: EXPERIMENTAL
Intervention: Bivalirudin (BIV) + 2-hour infusion after PCI
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Bivalirudin (BIV)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Glycoprotein IIb/IIIa receptor inhibitor (GPI)
Number of subjects: 346
Study: 19706207

Group type: EXPERIMENTAL
Intervention: Soya protein isolate (SPI)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 29
Study: 18761239

Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block with 0.35 mL/kg of 0.5% levobupivacaine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined cervical plexus block with 0.2 mL/kg of 0.5% levobupivacaine (deep) and 0.15 mL/kg (superficial)
Number of subjects: 12
Study: 15800312

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 126
Study: 11821603

Group type: EXPERIMENTAL
Intervention: Ropivacaine 200 mg dissolved in 100 ml saline
Number of subjects: 93

Group type: COMPARATOR
Intervention: Saline 100 mg
Number of subjects: 93
Study: 10765864

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 24): Irreversibly infected dentin was partially removed prior to the application of the bonding agent and restorative material.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (n = 24): All identifiable, irreversibly infected dentin was removed prior to the application of the bonding agent and restorative material.
Number of subjects: 48
Study: 7669483

Group type: EXPERIMENTAL
Intervention: Food (eating)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Isoprenaline (10 min i.v. infusion of 1 microgram min-1)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Adrenaline (10 min i.v. infusion of 1 microgram min-1)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Isomazole (p.o. administration of 40 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Meribendan (p.o. administration of 40 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Celiprolol (p.o. administration of 1200 mg)
Number of subjects: 61
Study: 2285629

Group type: EXPERIMENTAL
Intervention: Nifedipine (2 x 10 mg capsules three times daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nisoldipine (2 x 10 mg tablets once daily)
Number of subjects: 20
Study: 7023715

Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) 1.5 mg/kg on day 1 + ARA‐C 2 mg/kg on days 1‐5 (R1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) 1.5 mg/kg on days 1 and 2 + ARA‐C 2 mg/kg on days 4‐8 (R2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daunorubicin-DNA complex 1.5 mg/kg on days 1 and 2 + ARA‐C 2 mg/kg on days 4‐8 (R3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall remission frequency across all groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comparison of survival between R3 and R1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treatment with DNR-DNA complex vs free DNR
Number of subjects: 60
Study: 31862174

Group type: EXPERIMENTAL
Intervention: Intensive treatment group (SBP goal of <120 mmHg)
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Standard treatment group (SBP goal of <140 mmHg)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 1255
Study: 30852711

Group type: EXPERIMENTAL
Intervention: High School Transition Program (HSTP), N=241
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control group, N=256
Number of subjects: 497
Study: 28678966

Group type: EXPERIMENTAL
Intervention: 0.075% CPC and 0.28% zinc lactate (test group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.07% CPC (positive control)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Negative control mouthwash without CPC
Number of subjects: 120
Study: 25729623

Group type: EXPERIMENTAL
Intervention: Ciclesonide (200 µg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levocetirizine (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclesonide + Levocetirizine
Number of subjects: 0
Study: 23816671

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg 2 h prior to induction of anesthesia and 75 mg twice daily for 2 post-operative days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20881443

Group type: COMPARATOR
Intervention: Tobramycin 0.3%-dexamethasone 0.1%, 1 drop q.i.d.
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Tobramycin 0.3%-dexamethasone 0.1%, 1 drop q.i.d., plus ketorolac tromethamine 0.5%, 1 drop t.i.d.
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (tobramycin/dexamethasone)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Intervention group (tobramycin/dexamethasone plus ketorolac)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study: 20361645

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 0
Study: 17426398

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel + fluoridated dentifrice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 30
Study: 15328495

Group type: EXPERIMENTAL
Intervention: Topical suspension of bacterial antigens (Lantigen B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (physiological solution)
Number of subjects: 80